As you are likely aware, many people are using a class of drugs called GLP-1 receptor agonists for weight loss. One of the ...

After psychological side effects doomed the first generation of cannabinoid receptor 1–targeting drugs for weight loss, Novo ...

In phase 2, VK2735 reduced patients' weight by about 15% after 13 weeks of treatment and maintained a clean safety profile.

The drug, initially intended for use by diabetics, has soared in popularity as a result of the weight-loss effects.

It feels as though just about every celebrity in Hollywood is using Ozempic - but what effect does the controversial drug ...

Scholar Rock is also working on a treatment that helps preserve lean muscle that is often lost during rapid weight loss by patients taking the new class of GLP-1 drugs. Scholar Rock's stock is down 45 ...

"It's very, very clear that physician spending is not the problem in healthcare." -- Jen Brull, MD, president of the American ...

These new challengers are anticipated to account for roughly $70 billion of the total GLP-1 market, which is expected to be worth $200 billion by 2031. Our report on the obesity drug market ...

As Ozempic and other GLP-1 drugs explode in popularity, driven by their off-label use for rapid weight loss and viral social media trends, the pharmaceutical industry faces unprecedented challenges.

With a market cap of $27.1 billion, DexCom, Inc. (DXCM) is a leading medical device company, specializing in continuous ...

Nearly two-thirds (64%)  of Americans who have tried weight loss injections report the drugs as being “extremely effective” ...

Scholar Rock said on Monday its experimental drug apitegromab met the main goal of a late-stage trial in patients with a type of rare genetic disease, sending the company's shares surging in premarket ...